Compare ADMA Biologics Inc (ADMA) vs Altria Group Inc (MO) Price & Performance

ADMA Biologics IncTrade

Altria Group IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Altria Group Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Altria Group Inc trades at $65.14 (market cap $114.13B). The key difference: Altria Group Inc is far larger — about 52.4× ADMA Biologics Inc's market cap, and Altria Group Inc pays a 6.2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

	ADMA	MO
Market Cap	$2.18B	$114.13B
Sector	Health	Consumer Staples
52-Week High	$20.38	$74.92
52-Week Low	$7.60	$54.72
Enterprise Value	$2.25B	$136.34B
Dividend Yield	—	6.2%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Altria Group Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ADMA

View details →

Invesco's PEY ETF outperforms with a dividend-growth filter, offering higher returns and reliable income.24/7 Wall Street · 16 hours agoBullish Altria offers 6.3% yield with 60 years of dividend growth, trading at a low valuation amid regulatory risks.Seeking Alpha · 4 days agoBullish Altria shares drop after Q2 results miss estimates; investigation into possible misleading earnings outlook underwayPRNewsWire · 4 days agoBearish View details →

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).